UK: Chair Appointed for UK's New Emerging Science and Bioethics Advisory Committee

Posted 23 May 2012 | By Louise Zornoza 

The Chair of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), Sir Alisdair Breckenridge, has been appointed the first Chair of the newly established Emerging Science and Bioethics Advisory Committee (ESBAC).

The committee is tasked with providing advice to UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. 

Sir Alasdair's previous roles include Chair of the Committee on Safety of Medicines, Chair of the North West Regional Health Authority and Chair of the Joint Committee of Higher Medical Training. His appointment to ESBAC is for 2 years, with a time commitment of 2 to 3 committee meetings a year. There is no remuneration for the post. 

On accepting the appointment, Sir Alasdair said he was "delighted to accept this exciting and challenging role," and that "new science and technology always presents us with difficult questions."

Read more:

MHRA - Press statement: Sir Alasdair Breckenridge appointed Chair of Emerging Science and Bioethics Advisory Committee

More Breaking News from RegLink

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Most Viewed Articles